About
Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker of AD, and our system can detect it years or decades before amyloid appears in the brain.
Technologies
Outlook
Microsoft Office 365
Mobile Friendly
MailChimp
YouTube
Google Font API
Nginx
Google Analytics
WordPress.org
Remote
Keywords
early detection technology
eye technology
biotechnology
neurodegenerative diseases
amyloid
diagnostics
alzheimers disease
clinical research
medical technology
research
innovation
life sciences
medical equipment manufacturing
alzheimers disease detection
medical diagnostics
medical equipment and supplies manufacturing
fda approval process
biomarker detection
beta-amyloid detection
medical device development
biomarker discovery
b2c
patient care
medical devices
sapphire ii system
amyloid in the eye
ocular amyloid imaging
ocular biomarkers for neurodegeneration
laser eye scanning
d2c
Company Information
-
Employees 2
-
Founded 2019
-
Annual Revenue $2710000
-
Total Funding $41090000
Location
33 Boston Post Rd W, Marlborough, Massachusetts, United States, 01752
